moderate hypertension,
Showing 1 - 25 of >10,000
Hypertension Trial in Victor Harbor, Geelong (VB0004, Matching Placebo for VB0004)
Recruiting
- Hypertension
- VB0004
- Matching Placebo for VB0004
-
Victor Harbor, Melbourne, Australia
- +1 more
May 2, 2022
Primary Mild and Moderate Hypertension Trial in Suzhou (SPH3127)
Completed
- Primary Mild and Moderate Hypertension
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 6, 2022
Resistant Hypertension Trial in Madrid (Moderate-intensity interval training (MIIT), Moderate-intensity continuous training
Recruiting
- Resistant Hypertension
- Moderate-intensity interval training (MIIT)
- Moderate-intensity continuous training (MICT)
-
Madrid, SpainUniversidad Europea Madrid (UEM)
Oct 5, 2022
Chronic Kidney Disease(CKD), Uncontrolled Hypertension Trial in Tours (Antihypertensive algorithm, Standard of care)
Not yet recruiting
- Chronic Kidney Disease(CKD)
- Uncontrolled Hypertension
- Antihypertensive algorithm
- Standard of care
-
Tours, FranceDepartment of Nephrology, University Hospital of Tours
Feb 8, 2023
Hypertension Trial in Lahore (mild aerobic exercise, moderate aerobic exercise)
Completed
- Hypertension
- mild aerobic exercise
- moderate aerobic exercise
-
Lahore, Punjab, PakistanRiphah Rehabilitation Center
Dec 7, 2022
Portal Hypertension Trial in Nanjing (Endoscopy+NSBBs, Transjugular intrahepatic portosystemic shunt)
Recruiting
- Portal Hypertension
- Endoscopy+NSBBs
- Transjugular intrahepatic portosystemic shunt
-
Nanjing, Jiangsu, ChinaNanjing Drum Tower Hospital
Aug 22, 2023
CTEPH Trial in Murray
Recruiting
- CTEPH
-
Murray, UtahIntermountain Medical Center
Oct 23, 2023
Hypertension Trial (MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks)
Completed
- Hypertension
- MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks
- (no location specified)
Feb 7, 2022
Hypertension Trial (Losartan 50 mg / HCTZ 12.5 mg)
Completed
- Hypertension
- Losartan 50 mg / HCTZ 12.5 mg
- (no location specified)
Feb 7, 2022
Essential Hypertension Trial in China (SPH3127 tablet, Valsartan)
Recruiting
- Essential Hypertension
- SPH3127 tablet
- Valsartan
-
Beijing, Beijing, China
- +13 more
May 4, 2022
Chronic Kidney Disease, Hypertension Trial in Multiple Locations (BAY3283142, Placebo to BAY3283142)
Not yet recruiting
- Chronic Kidney Disease
- Hypertension
- BAY3283142
- Placebo to BAY3283142
-
Multiple Locations, Bulgaria
- +1 more
Aug 5, 2022
Erectile Dysfunction, Pulmonary Arterial Hypertension Trial in Changchun (TPN171H)
Completed
- Erectile Dysfunction
- Pulmonary Arterial Hypertension
-
Changchun, ChinaThe First Affiliated Hospital of Jilin University
Mar 22, 2022
Hypertension, Pregnancy-Induced, Pre-Eclampsia Trial in Maastricht (Labetalol, Nifedipine, Methyldopa)
Recruiting
- Hypertension, Pregnancy-Induced
- Pre-Eclampsia
- Labetalol
- +2 more
-
Maastricht, NetherlandsMaastricht UMC
Mar 23, 2021
Pre-Eclampsia in Nigeria: A Explanatory Sequential Mixed Methods
Not yet recruiting
- Hypertensive Disorders of Pregnancy
- Exposure of interest - Moderate or High-risk Preeclampsia
-
Abuja, Nigeria
- +3 more
Sep 20, 2023
Essential Hypertension Trial in Shenzhen (Sacubatril Allisartan medoxomil, Olmesartan Medoxomil)
Recruiting
- Essential Hypertension
- Sacubatril Allisartan medoxomil
- Olmesartan Medoxomil
-
Shenzhen, Guangdong, ChinaShenzhen People' S Hospital
Aug 30, 2021
Precapillary Pulmonary Hypertension, Interstitial Lung Disease Trial in Zurich (Moderate altitude sojourn, Low altitude sojourn,
Completed
- Precapillary Pulmonary Hypertension
- Interstitial Lung Disease
- Moderate altitude sojourn
- +3 more
-
Zurich, SwitzerlandUniversity Hospital Zurich, Pulmonary Division
Oct 6, 2021
Intracranial Hypertension Trial (Ultrasonographic measurement of optic nerve sheath diameter, Deep neuromuscular block, Moderate
Not yet recruiting
- Intracranial Hypertension
- Ultrasonographic measurement of optic nerve sheath diameter
- +2 more
- (no location specified)
Sep 6, 2021
Essential Hypertension Trial (AZM X mg + AML Y mg, AZM X mg + AML Y' mg, AZM X' mg + AML Y mg)
Not yet recruiting
- Essential Hypertension
- AZM X mg + AML Y mg
- +7 more
- (no location specified)
May 25, 2022
Hypertension,Essential Trial in China (SPH3127 tablet Dose 1, SPH3127 tablet Dose 2, SPH3127 tablet Dose 3)
Completed
- Hypertension,Essential
- SPH3127 tablet Dose 1
- +3 more
-
Beijing, China
- +9 more
Nov 11, 2021
Chronic Kidney Diseases, Hypertension Trial in Princeton, Morrisville (KBP-5074 0.25 mg tablet, KBP-5074 0.5 mg tablet)
Completed
- Chronic Kidney Diseases
- Hypertension
- KBP-5074 0.25 mg tablet
- KBP-5074 0.5 mg tablet
-
Princeton, New Jersey
- +1 more
Sep 27, 2021
Chronic Kidney Diseases, Chronic Disease, Chronic Kidney Disease, Stage 3 (Moderate) Trial in United States (Control-EDI,
Recruiting
- Chronic Kidney Diseases
- +4 more
- Control-EDI
- Intervention-EDI and health coaching
-
Ann Arbor, Michigan
- +10 more
Aug 30, 2022
Essential Hypertension ( Mild to Moderate) Trial in Worldwide (Aliskiren, Hydrochlorothiazide, Amlodipine)
Completed
- Essential Hypertension ( Mild to Moderate)
- Aliskiren
- +2 more
-
Paris, France
- +3 more
Jul 23, 2020
Hypertension Trial in France (period with drug (trade name) then period with generic, period with generic then period with drug
Completed
- Hypertension
- period with drug (trade name) then period with generic
- period with generic then period with drug (trade name)
-
Annonay, France
- +7 more
Sep 23, 2021
Symptomatic Neurogenic Orthostatic Hypertension, nOH Trial in Miami, Orlando (Ampreloxetine)
Completed
- Symptomatic Neurogenic Orthostatic Hypertension
- nOH
-
Miami, Florida
- +1 more
Sep 7, 2021